Cancer Survivors Lack Dermatologic Support: The Visible Toll of Oncology Treatments

For the growing number of people who have completed cancer treatment, the visible marks left by chemotherapy, radiation, and targeted therapies often outlast the disease itself—yet dedicated dermatological care in the survivorship setting remains largely unavailable.

A narrative review published in the American Journal of Clinical Dermatology examined the scope of long-lasting skin, hair, nail, and mucosal changes in cancer survivors and evaluated available restorative and corrective interventions for each condition. The authors concluded that structured dermatological follow-up for this population represents a critical and largely unmet clinical need.

Surviving Treatment Is Only Half the Battle

As oncological therapies have improved survival rates, clinical attention has shifted from managing acute treatment toxicities to addressing the chronic sequelae that persist months or years after treatment ends. Despite this shift in the patient population, most supportive oncodermatology programs have been developed and studied exclusively in the active treatment setting. Evidence specifically evaluating the impact of structured dermatological care on long-term sequelae in survivors has remained sparse, and dedicated survivorship-oriented dermatological programs are rarely implemented in practice.

The Damage That Outlasts the Disease

The review covered dermatological sequelae associated with chemotherapy, radiotherapy, targeted therapies, immunotherapy, endocrine treatments, and hematopoietic stem cell transplantation (HSCT). The authors found that chronic skin-related conditions were common across all treatment modalities and had documented negative effects on quality of life, body image, and psychological well-being.

Among the data cited, up to 59% of adult survivors of childhood cancer reported chronic skin-related problems, and approximately 30% reported visible scarring or disfigurement long after treatment completion. In the same population, persistent chemotherapy-induced alopecia (pCIA) was reported in approximately 12% to 15% of childhood cancer survivors, particularly following conditioning regimens with thiotepa and busulfan.

In breast cancer survivors receiving aromatase inhibitors, endocrine therapy–induced alopecia was reported in approximately 15% to 25% of patients. Hot flashes affected roughly 30% to 50% of patients on endocrine therapy, while among men receiving androgen deprivation therapy for prostate cancer, vasomotor symptoms occurred in approximately 58% to 80% of cases. Dry mouth was reported in up to 67% of head and neck cancer survivors following radiation therapy.

For people treated with taxanes, chronic onycholysis and nail fragility were identified as among the most persistent and underreported long-term nail sequelae. Radiation-induced telangiectasias rarely regressed spontaneously and were described as a stable late sequela that significantly affected dermatology-specific quality of life.

The authors also highlighted secondary skin cancers as a serious long-term concern, particularly basal cell carcinoma and squamous cell carcinoma, which may develop after latency periods exceeding 10 to 15 years following radiotherapy or combined modality treatment.

Children Bear a Disproportionate Burden

The review addressed a broad survivorship population, with particular attention to childhood and adolescent cancer survivors, who the authors identified as especially vulnerable. This group faces longer life expectancy after treatment, meaning a prolonged period of exposure to treatment-related carcinogenic effects and a greater cumulative burden from visible sequelae during identity-forming developmental years.

Pediatric oncology experts have increasingly warned that cancer therapies can leave children with a wide spectrum of long-lasting skin, hair, nail, and mucosal complications that extend far beyond active treatment.² Reviews of pediatric cancer care have documented persistent dermatologic toxicities ranging from alopecia and pigmentary changes to chronic xerosis, mucositis, nail disorders, and painful rashes, many of which can impair quality of life and psychosocial development during formative years. Researchers have noted that because children often survive for decades after treatment, these visible sequelae may carry especially profound emotional and social consequences throughout adolescence and adulthood.

Evidence Remains Thin Across the Board

As a narrative review, the paper was subject to the limitations inherent to that design, including selective literature inclusion and the absence of a systematic search methodology.¹ The authors acknowledged that most recommendations for restorative dermatological interventions were based on limited or heterogeneous evidence, often derived from small case series, expert opinion, or extrapolation from nononcological dermatological conditions. The authors called for future prospective studies and controlled trials to better define the efficacy and safety of these interventions in cancer survivors.

Researchers Make the Case for Dedicated Care

The authors were direct about the gap between patient need and current practice. "Recognizing and managing dermatological sequelae is an essential component of modern survivorship care, and dermatologists should play a central role in multidisciplinary follow-up programs dedicated to cancer survivors," they wrote.

The paper proposed a 6-step algorithm for dermatological survivorship assessment, covering treatment history, identification of sequelae, clinical prioritization, full dermatological evaluation, management planning, and long-term follow-up. The authors emphasized that this framework should include not only restorative interventions but also ongoing surveillance for secondary skin cancers and psychological support for appearance-related distress.

References

1. Rapparini L, Touhouche TA, Fattore D, et al. Corrective and restorative dermatology in cancer survivors: an urgent unmet need! Am J Clin Dermatol. 2026;27(3):515-535. doi:10.1007/s40257-026-01027-0

2. Sous D, Armstrong AE, Huang JT, Shah S, Carlberg VM, Coughlin CC. Cutaneous reactions to pediatric cancer treatment: part I. Conventional chemotherapy. Pediatr Dermatol. 2021;38(1):8-17. doi:10.1111/pde.14418